DiaMedica Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

DiaMedica Therapeutics's earnings are forecast to decline at 26.4% per annum. Der Gewinn pro Aktie wird voraussichtlich sinken um 13.8% pro Jahr.

Wichtige Informationen

-26.4%

Wachstumsrate der Gewinne

-13.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.2%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	27 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

May 16

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 12

FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold

Jul 06

We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

Jun 16

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 04

DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.

Nov 05

DiaMedica: Undercovered Stroke Drug Company With Decent Data

Jun 13

We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

May 01

Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

Feb 13

We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

Jan 09

DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:DMAC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-40	N/A	N/A	1
12/31/2025	N/A	-35	N/A	N/A	2
12/31/2024	N/A	-26	N/A	N/A	3
3/31/2024	N/A	-19	-20	-20	N/A
12/31/2023	N/A	-19	-19	-19	N/A
9/30/2023	N/A	-18	-18	-18	N/A
6/30/2023	N/A	-17	-15	-15	N/A
3/31/2023	N/A	-15	-13	-13	N/A
12/31/2022	N/A	-14	-12	-12	N/A
9/30/2022	N/A	-13	-12	-12	N/A
6/30/2022	N/A	-14	-12	-12	N/A
3/31/2022	N/A	-13	-12	-12	N/A
12/31/2021	N/A	-14	-12	-12	N/A
9/30/2021	N/A	-15	-13	-12	N/A
6/30/2021	N/A	-14	-12	-12	N/A
3/31/2021	N/A	-13	-11	-11	N/A
12/31/2020	N/A	-12	-9	-9	N/A
9/30/2020	N/A	-11	-8	-8	N/A
6/30/2020	N/A	-10	-7	-7	N/A
3/31/2020	N/A	-10	-9	-9	N/A
12/31/2019	N/A	-11	-9	-9	N/A
9/30/2019	N/A	-10	-9	-9	N/A
6/30/2019	1	-9	-10	-10	N/A
3/31/2019	1	-8	-8	-8	N/A
12/31/2018	1	-6	-6	-6	N/A
9/30/2018	1	-5	-5	-5	N/A
6/30/2018	N/A	-4	-4	-4	N/A
3/31/2018	N/A	-4	-4	-4	N/A
12/31/2017	N/A	-4	N/A	-4	N/A
9/30/2017	N/A	-4	N/A	-4	N/A
6/30/2017	N/A	-4	N/A	-4	N/A
3/31/2017	N/A	-3	N/A	-3	N/A
12/31/2016	N/A	-2	N/A	-3	N/A
9/30/2016	N/A	-2	N/A	-2	N/A
6/30/2016	N/A	-2	N/A	-2	N/A
3/31/2016	N/A	-1	N/A	-2	N/A
12/31/2015	N/A	-2	N/A	-2	N/A
9/30/2015	N/A	-2	N/A	-1	N/A
6/30/2015	N/A	-2	N/A	-2	N/A
3/31/2015	N/A	-3	N/A	-3	N/A
12/31/2014	N/A	-5	N/A	-4	N/A
9/30/2014	N/A	-5	N/A	-4	N/A
6/30/2014	N/A	-6	N/A	-5	N/A
3/31/2014	N/A	-7	N/A	-5	N/A
12/31/2013	N/A	-7	N/A	-6	N/A
9/30/2013	N/A	-9	N/A	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DMAC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: DMAC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: DMAC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von DMAC schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: DMAC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von DMAC in 3 Jahren voraussichtlich hoch sein wird

DiaMedica Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Price target decreased by 16% to US$7.00

Price target increased by 11% to US$8.33

Price target decreased by 13% to US$7.00

No longer forecast to breakeven

Forecast to breakeven in 2025

Recent updates

DiaMedica Therapeutics Inc. announced that it expects to receive $11.8 million in funding

DiaMedica Therapeutics Inc. Plans to Expand Its Clinical Trials into Preeclampsia

New minor risk - Market cap size

New minor risk - Share price stability

DiaMedica Therapeutics Inc. Elects Rick Pauls as Director

DiaMedica Therapeutics Inc. to Report Q1, 2024 Results on May 08, 2024

No longer forecast to breakeven

DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Price target decreased by 16% to US$7.00

DiaMedica Therapeutics Inc., Annual General Meeting, May 22, 2024

DiaMedica Therapeutics Inc. Appoints Dr. Lorianne Masuoka as Chief Medical Officer

DiaMedica Therapeutics Inc. to Report Q3, 2023 Results on Nov 13, 2023

DiaMedica Therapeutics Inc. Announces the Appointment of Ambarish Shah as Chief Technology Officer

DiaMedica Therapeutics Inc. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Share price stability

New minor risk - Shareholder dilution

Chief Business Officer recently bought US$150k worth of stock

Price target increased by 11% to US$8.33

DiaMedica Therapeutics Inc. announced that it expects to receive $37.43878 million in funding

Price target decreased by 13% to US$7.00

Diamedica Therapeutics Announces Appointment of Richard Kuntz to the Board of Directors

Diamedica Therapeutics Inc. Files Complete Clinical Hold Response with the U.S. Food and Drug Administration Regarding the Status of the Remedy2 Study

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

DiaMedica Therapeutics Inc. to Report Q1, 2023 Results on May 15, 2023

Insider recently bought US$750k worth of stock

No longer forecast to breakeven

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Forecast to breakeven in 2025

Independent Director recently bought US$80k worth of stock

Price target decreased to US$10.67

DiaMedica Therapeutics Inc. Provides Update on Remedy2 Trial

DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations

DiaMedica Therapeutics Inc. to Report Q2, 2022 Results on Aug 10, 2022

No longer forecast to breakeven

DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199

FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold

We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

Diamedica Therapeutics Inc. Announces Resignation of Harry Alcorn, Jr. , Senior Vice President of Clinical Operations

Price target decreased to US$13.25

High number of new and inexperienced directors

High number of new and inexperienced directors

Price target decreased to US$15.80

DiaMedica Therapeutics Inc., Annual General Meeting, May 18, 2022

DiaMedica Therapeutics Inc. Appoints Dominic Cundari as Chief Commercial Officer

Price target increased to US$20.00

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Forecast to breakeven in 2024

DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.

Price target decreased to US$20.40

Chief Medical Officer recently bought US$57k worth of stock

DiaMedica Therapeutics Inc. Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke

Chief Medical Officer recently bought US$64k worth of stock

DiaMedica Therapeutics Inc. Announces Positive Interim Results from Phase 2 REDUX Study in CKD

DiaMedica Therapeutics Inc.(NasdaqCM:DMAC) dropped from Russell 3000E Value Index

DiaMedica: Undercovered Stroke Drug Company With Decent Data

DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke

We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

Price target increased to US$25.00

DiaMedica Therapeutics Inc. to Report Q4, 2020 Results on Mar 10, 2021

DiaMedica Therapeutics Inc., Annual General Meeting, May 25, 2021

New 90-day high: US$10.42

Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

New 90-day high: US$10.30

We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

Price target raised to US$18.25

DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study

DiaMedica Therapeutics Inc. Announces Successful Type B Meeting with FDA for the Study of DM199 in Patients with Acute Ischemic Stroke